Outcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: No intervention
- Registration Number
- NCT04931992
- Lead Sponsor
- University Hospital, Angers
- Brief Summary
Despite good initial response, some patients with core binding factor and/or NPM1-mutated AML eventually relapse. Some of these patients can be identified earlier on, before overt cytological relapse, when followed for minimal residual disease. The outcome of patients treated when molecular relapse is confirmed, before overt cytological relapse, is not well known. This multi-center retrospective will therefore study the outcome of these patients and try to specify the role of allogeneic stem cell transplantation in this setting.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patients between 18 and 61 years
- Diagnosis between 2010 and 2019
- Core binding factor and/or NPM1 acute myeloid leukemia
- First complete remission after induction therapy
- Measurable residual disease measurement after end of consolidation therapy
Exclusion Criteria
- Acute promyelocytic leukemia
- Allogeneic stem cell transplantation in CR1
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cytological relapse No intervention Overt cytological relapse, without prior molecular relapse Molecular relapse No intervention Confirmed molecular relapse, without overt cytological relapse Persistent responders No intervention No molecular or cytological relapse during follow-up
- Primary Outcome Measures
Name Time Method Event-free survival Up to 5 years
- Secondary Outcome Measures
Name Time Method Overall survival Up to 5 years
Trial Locations
- Locations (1)
Angers University Hospital
🇫🇷Angers, France